Table 4.

Sensitivity analysis using nested case crossover design of hypersensitivity reactions associated with biologics for rheumatoid arthritis

Administration type	Treatments	Comparison of exposure within 0–1 days of the event compared to other time periods Odds ratio (95% CI)	Between-drug comparison, Odds Ratio (95% CI)
Intravenous	Abatacept	13.2 (6.5 – 26.9)	21.3 (6.0 – 168.6)
	Infliximab	15.4 (9.8 – 24.3)	24.8 (9.1 – 121.7)
	Rituximab	19.0 (8.3 – 73.8)	30.6 (7.8 – 254.9)
	Tocilizumab	15.8 (6.7 – 37.5)	25.5 (6.4 – 218.8)
Subcutaneous	Anti-TNF*	0.62 (0.15– 2.56)	Ref (1.0)

^*etanercept, adalimumab, certolizumab and golimumab